Diuretics - Mineralocorticoid Receptor Antagonist (MRA)

Mineralocorticoid receptor antagonists (MRAs), historically categorized as potassium-sparing diuretics or aldosterone antagonists, are a pharmacologic class that competitively inhibits the binding of aldosterone to mineralocorticoid receptors in the distal convoluted tubule and collecting duct By blocking aldosterone-dependent sodium-potassium exchange, these agents increase urinary excretion of sodium and water while conserving potassium and hydrogen ions, concurrently mitigating adverse aldost...

Mineralocorticoid receptor antagonists (MRAs), historically categorized as potassium-sparing diuretics or aldosterone antagonists, are a pharmacologic class that competitively inhibits the binding of aldosterone to mineralocorticoid receptors in the distal convoluted tubule and collecting duct Clinically, members of this class are utilized in the management of hypertension, edema associated with hepatic cirrhosis or nephrotic syndrome, primary hyperaldosteronism, and heart failure with reduced e...

Mineralocorticoid receptor antagonists (MRAs), historically categorized as potassium-sparing diuretics or aldosterone antagonists, are a pharmacologic class that competitively inhibits the binding of aldosterone to mineralocorticoid receptors in the distal convoluted tubule and collecting duct By blocking aldosterone-dependent sodium-potassium exchange, these agents increase urinary excretion of sodium and water while conserving potassium and hydrogen ions, concurrently mitigating adverse aldost...

By blocking aldosterone-dependent sodium-potassium exchange, these agents increase urinary excretion of sodium and water while conserving potassium and hydrogen ions, concurrently mitigating adverse aldosterone-mediated cardiac and vascular remodeling

Clinically, members of this class are utilized in the management of hypertension, edema associated with hepatic cirrhosis or nephrotic syndrome, primary hyperaldosteronism, and heart failure with reduced ejection fraction, with newer nonsteroidal agents indicated to reduce cardiorenal risks in chronic kidney disease